Literature DB >> 30262564

Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.

Richárd Kiss1, Donát Alpár1, Ambrus Gángó1, Noémi Nagy1, Ediz Eyupoglu1, Dóra Aczél1, András Matolcsy1, Judit Csomor1, Zoltán Mátrai2, Csaba Bödör3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30262564      PMCID： PMC6312015          DOI： 10.3324/haematol.2018.202085

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

2.  Acquired initiating mutations in early hematopoietic cells of CLL patients.

Authors:  Frederik Damm; Elena Mylonas; Adrien Cosson; Kenichi Yoshida; Véronique Della Valle; Enguerran Mouly; M'boyba Diop; Laurianne Scourzic; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Yoshikane Kikushige; Frederick Davi; Jérôme Lambert; Daniel Gautheret; Hélène Merle-Béral; Laurent Sutton; Philippe Dessen; Eric Solary; Koichi Akashi; William Vainchenker; Thomas Mercher; Nathalie Droin; Seishi Ogawa; Florence Nguyen-Khac; Olivier A Bernard
Journal:  Cancer Discov       Date:  2014-06-11       Impact factor: 39.397

3.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

4.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Authors:  Mohammed Z H Farooqui; Janet Valdez; Sabrina Martyr; Georg Aue; Nakhle Saba; Carsten U Niemann; Sarah E M Herman; Xin Tian; Gerald Marti; Susan Soto; Thomas E Hughes; Jade Jones; Andrew Lipsky; Stefania Pittaluga; Maryalice Stetler-Stevenson; Constance Yuan; Yuh Shan Lee; Lone B Pedersen; Christian H Geisler; Katherine R Calvo; Diane C Arthur; Irina Maric; Richard Childs; Neal S Young; Adrian Wiestner
Journal:  Lancet Oncol       Date:  2014-12-31       Impact factor: 41.316

5.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.

Authors:  Anna Schuh; Jennifer Becq; Sean Humphray; Adrian Alexa; Adam Burns; Ruth Clifford; Stephan M Feller; Russell Grocock; Shirley Henderson; Irina Khrebtukova; Zoya Kingsbury; Shujun Luo; David McBride; Lisa Murray; Toshi Menju; Adele Timbs; Mark Ross; Jenny Taylor; David Bentley
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

6.  Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).

Authors:  Natalia L Komarova; Jan A Burger; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-08       Impact factor: 11.205

Review 7.  Clonal evolution in hematological malignancies and therapeutic implications.

Authors:  D A Landau; S L Carter; G Getz; C J Wu
Journal:  Leukemia       Date:  2013-08-27       Impact factor: 11.528

8.  Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.

Authors:  Adam Albitar; Wanlong Ma; Ivan DeDios; Jeffrey Estella; Inhye Ahn; Mohammed Farooqui; Adrian Wiestner; Maher Albitar
Journal:  Oncotarget       Date:  2017-03-14

9.  Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Authors:  Jan A Burger; Dan A Landau; Amaro Taylor-Weiner; Ivana Bozic; Huidan Zhang; Kristopher Sarosiek; Lili Wang; Chip Stewart; Jean Fan; Julia Hoellenriegel; Mariela Sivina; Adrian M Dubuc; Cameron Fraser; Yulong Han; Shuqiang Li; Kenneth J Livak; Lihua Zou; Youzhong Wan; Sergej Konoplev; Carrie Sougnez; Jennifer R Brown; Lynne V Abruzzo; Scott L Carter; Michael J Keating; Matthew S Davids; William G Wierda; Kristian Cibulskis; Thorsten Zenz; Lillian Werner; Paola Dal Cin; Peter Kharchencko; Donna Neuberg; Hagop Kantarjian; Eric Lander; Stacey Gabriel; Susan O'Brien; Anthony Letai; David A Weitz; Martin A Nowak; Gad Getz; Catherine J Wu
Journal:  Nat Commun       Date:  2016-05-20       Impact factor: 14.919

10.  Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations.

Authors:  R Rosenquist; P Ghia; A Hadzidimitriou; L-A Sutton; A Agathangelidis; P Baliakas; N Darzentas; V Giudicelli; M-P Lefranc; A W Langerak; C Belessi; F Davi; K Stamatopoulos
Journal:  Leukemia       Date:  2017-04-25       Impact factor: 11.528
View more
  4 in total

1.  Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.

Authors:  Ákos Nagy; Bence Bátai; Alexandra Balogh; Sarolta Illés; Gábor Mikala; Noémi Nagy; Laura Kiss; Lili Kotmayer; András Matolcsy; Donát Alpár; Tamás Masszi; András Masszi; Csaba Bödör
Journal:  Genes (Basel)       Date:  2020-07-13       Impact factor: 4.096

Review 2.  Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Authors:  Bartosz Puła; Aleksandra Gołos; Patryk Górniak; Krzysztof Jamroziak
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

3.  Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.

Authors:  Ferenc Takács; Lili Kotmayer; Ágnes Czeti; Gábor Szalóki; Tamás László; Gábor Mikala; Ágnes Márk; András Masszi; Péter Farkas; Márk Plander; Júlia Weisinger; Judit Demeter; Sándor Fekete; László Szerafin; Beáta Margit Deák; Erika Szaleczky; Adrienn Sulák; Zita Borbényi; Gábor Barna
Journal:  Pathol Oncol Res       Date:  2022-09-21       Impact factor: 2.874

Review 4.  [Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].

Authors:  C J Ye; W B Xu; Q Yu; C Wu; L Huang; J M Li; H Yan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.